2.24  -0.22 (-8.94%)		03-12 16:00
Open: 2.45 High: 2.46 Volume: 585,247		Pre. Close: 2.46 Low: 2.23 Market Cap: 630(M)

Short term
Mid term
Targets	6-month :	3.04	1-year :	3.55
Resists	First :	2.6	Second :	3.04
Pivot price	2.29
Supports	First :	2.05	Second :	1.71
MAs	MA(5) :	2.37	MA(20) :	2.23
	MA(100) :	2.37	MA(250) :	2.01
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	62	D(3) :	69.5
RSI	RSI(14): 49.8
52-week	High :	7.13	Low :	0.46

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PROK ] has closed above bottom band by 37.6%. Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.46 - 2.48	2.48 - 2.49
Low:	2.2 - 2.22	2.22 - 2.23
Close:	2.22 - 2.24	2.24 - 2.26

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Wed, 25 Feb 2026
ProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Hold" by Analysts - MarketBeat

Sat, 27 Dec 2025
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance

Mon, 10 Nov 2025
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewswire

Mon, 20 Oct 2025
ProKidney Corp. to Present Late-Breaking Phase 2 REGEN-007 Study Results at ASN Kidney Week 2025 - Quiver Quantitative

Fri, 19 Sep 2025
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha

Wed, 09 Jul 2025
Individual investors who hold 32% of ProKidney Corp. (NASDAQ:PROK) gained 560%, institutions profited as well - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	142 (M)
Held by Insiders	9.327e+007 (%)
Held by Institutions	25.3 (%)
Shares Short	15,250 (K)
Shares Short P.Month	0 (K)

EPS	-1.6458e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-17 %
Return on Assets (ttm)	613.3 %
Return on Equity (ttm)	-25.9 %
Qtrly Rev. Growth	744000 %
Gross Profit (p.s.)	0
Sales Per Share	-23.23
EBITDA (p.s.)	413333
Qtrly Earnings Growth	-0.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-112 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.1
Price to Cash Flow	-0.55

Dividend	0
Forward Dividend	1.621e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.